{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:11:01Z","timestamp":1778721061449,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571422"],"award-info":[{"award-number":["32571422"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109875","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:07:49Z","timestamp":1776233269000},"page":"109875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis, biological evaluation, and mechanism investigation of multisubstituted quinazoline analogues as prospective inhibitors of KRAS G12D"],"prefix":"10.1016","volume":"176","author":[{"given":"Xiu-Juan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Ran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109875_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109875_bb0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109875_bb0015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/cdd.2014.34","article-title":"Novel signaling axis for ROS generation during K-Ras-induced cellular transformation","volume":"21","author":"Park","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2026.109875_bb0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/med.21734","article-title":"Small molecules regulating reactive oxygen species homeostasis for cancer therapy","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.109875_bb0025","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/15548627.2024.2307224","article-title":"A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS","volume":"20","author":"Iskandar","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.bioorg.2026.109875_bb0030","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1021\/acs.chemrev.5b00542","article-title":"Ras conformational ensembles, allostery, and signaling","volume":"116","author":"Lu","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.109875_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118354","article-title":"Discovery of novel pyrimidine-based KRAS-G12C inhibitors with potent anti-NSCLC activity via virtual screening and structure optimization","volume":"302","author":"Shi","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109875_bb0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109875_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108050","article-title":"Resistance looms for KRAS G12C inhibitors and rational tackling strategies","volume":"229","author":"Zhang","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109875_bb0055","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109875_bb0060","doi-asserted-by":"crossref","first-page":"1013902","DOI":"10.3389\/fonc.2022.1013902","article-title":"KRAS G12D targeted therapies for pancreatic cancer: has the fortress been conquered?","volume":"12","author":"Bannoura","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109875_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13543784.2023.2178419","article-title":"Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy","volume":"32","author":"Zhang","year":"2023","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.109875_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118555","article-title":"An overview of KRAS G12D inhibitors: expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities","volume":"305","author":"Kumar","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0075","first-page":"955","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations, trends","volume":"9","author":"Zeissig","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109875_bb0080","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) t cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109875_bb0085","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.bioorg.2026.109875_bb0095","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1021\/acs.jmedchem.3c01724","article-title":"Design, synthesis, and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRASG12D inhibitors","volume":"66","author":"Xiao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109875_bb0105","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1021\/acs.jmedchem.4c02662","article-title":"Discovery of INCB159020, an orally bioavailable KRAS G12D inhibitor","volume":"68","author":"Ye","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0110","first-page":"466","article-title":"Discovery of pyrazoloquinazoline analogues as orally bioavailable KRAS-G12D inhibitors","volume":"69","author":"Song","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118004","article-title":"The design and synthesis of selective and potent selenium-containing KRAS(G12D) inhibitors","volume":"298","author":"Zhou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114243","article-title":"Discovery of thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening","volume":"233","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107460","article-title":"Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors","volume":"148","author":"Sun","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0130","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1158\/1538-7445.AM2024-3318","article-title":"Abstract 3318: GFH375 (VS-7375): An oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy","volume":"84","author":"Yan","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109875_bb0135","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1538-7445.AM2024-3316","article-title":"Abstract 3316: LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models","volume":"84","author":"Gong","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109875_bb0140","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1158\/1538-7445.AM2024-5900","article-title":"Abstract 5900: INCB161734: a novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors","volume":"84","author":"Farren","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109875_bb0145","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1158\/1538-7445.AM2024-3315","article-title":"Abstract 3315: preclinical studies of TSN1611, a potent, selective, and orally bioavailable KRASG12D inhibitor","volume":"84","author":"Shang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109875_bb0150","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB321","article-title":"Abstract LB321: discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor","volume":"83","author":"Vo","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109875_bb0155","doi-asserted-by":"crossref","first-page":"ND03","DOI":"10.1158\/1538-7445.AM2024-ND03","article-title":"Abstract ND03: discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor","volume":"84","author":"Knox","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109875_bb0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.ads2150","article-title":"KRAS takes the road to destruction","volume":"385","author":"Cox","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109875_bb0165","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1021\/acs.jmedchem.3c01724","article-title":"Design, synthesis, and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRAS(G12D) inhibitors","volume":"66","author":"Xiao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0170","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41416-024-02586-x","article-title":"Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors","volume":"130","author":"Baranyi","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109875_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107467","article-title":"Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and rational structural optimization","volume":"148","author":"Shi","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0180","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","article-title":"Feedback activation of EGFR\/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer","volume":"42","author":"Feng","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109875_bb0185","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1089\/ars.2015.6362","article-title":"Synthetic lethality of a novel small molecule against mutant KRAS-expressing cancer cells involves AKT-dependent ROS production","volume":"24","author":"Iskandar","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bioorg.2026.109875_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117551","article-title":"Structural simplification of quaternary benzophenanthridine alkaloids generating a candidate for the treatment of non-small cell lung cancer","volume":"290","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108329","article-title":"Berberrubine as a novel TrxR inhibitor enhances cisplatin sensitivity in the treatment of non-small cell lung cancer","volume":"158","author":"Chu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114415","article-title":"Mechanism of vitamin b6 benzoyl hydrazone platinum(II) complexes overcomes multidrug resistance in lung cancer","volume":"237","author":"Qi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0205","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.biopha.2018.10.161","article-title":"Puerarin attenuates neurological deficits via Bcl-2\/Bax\/cleaved caspase-3 and Sirt3\/SOD2 apoptotic pathways in subarachnoid hemorrhage mice","volume":"109","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109875_bb0210","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1021\/acs.jmedchem.2c00133","article-title":"Copper(II) complexes of halogenated quinoline schiff base derivatives enabled cancer therapy through glutathione-assisted chemodynamic therapy and inhibition of autophagy flux","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0215","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/10286020.2024.2343821","article-title":"Kawsar, flavonoids as potential KRAS inhibitors: DFT, molecular docking, molecular dynamics simulation and ADMET analyses","volume":"26","author":"Prinsa","year":"2024","journal-title":"J. Asian Nat. Prod. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109875_bb0220","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1021\/acs.jmedchem.5c02564","article-title":"Discovery of potent o-aminobenzoamide-based NAMPT inhibitors for targeting NAPRT-deficient gastric cancer","volume":"69","author":"Yang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109875_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143641","article-title":"Discovery of flavopiridol as a noncovalent thioredoxin reductase inhibitor through in silico and in vitro approach","volume":"311","author":"Zhou","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2026.109875_bb0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cpan.2025.11.001","article-title":"Identification of potential anti-tubercular inhibitors through virtual screening, DFT, and molecular dynamics simulation studies","volume":"22","author":"Nyijime","year":"2026","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.bioorg.2026.109875_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2023.102537","article-title":"Exploring the effectiveness of flavone derivatives for treating liver diseases: utilizing DFT, molecular docking, and molecular dynamics techniques","volume":"12","author":"Quayum","year":"2024","journal-title":"MethodsX"},{"key":"10.1016\/j.bioorg.2026.109875_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118066","article-title":"Discovery of protein arginine methyltransferase 1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular dynamics simulations, and the enhancement of paclitaxel\u2019s antitumor activity","volume":"299","author":"Su","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:36:30Z","timestamp":1778718990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S0045206826004116"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109875","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, biological evaluation, and mechanism investigation of multisubstituted quinazoline analogues as prospective inhibitors of KRAS G12D","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109875"}}